Clinical Trials Logo

Nausea clinical trials

View clinical trials related to Nausea.

Filter by:

NCT ID: NCT05590923 Recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

Start date: December 7, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this research is to compare two drugs that are routinely used as standard of care for treating nausea and vomiting caused by chemotherapy. This study aims to see if the drug olanzapine is as good as the steroid drug dexamethasone for preventing nausea and vomiting after chemotherapy. Both drugs are listed as appropriate treatment options in the most recent version of National Comprehensive Cancer Network guidelines on Antiemesis.

NCT ID: NCT05585086 Not yet recruiting - Inhalation; Oil Clinical Trials

Effect of Peppermint Oil Inhalation on Postoperative Nausea, Vomiting and Comfort

Start date: December 20, 2022
Phase: N/A
Study type: Interventional

Nausea and vomitting related to drugs and anesthetic methods are among the important postoperative problems. Nausea and vomitting causing illlness feeling of patient are frequent after surgical interventions, cause increased dissatisfaction of the patient and prolonged discharge period. In this study it was aimed to evaluate the effect of peppermint oil inhalation on postoperative nausea and vomitting. Purpose and Type of Research The randomized controlled study will be performed on patients undergoing laparoscopic cholecystectomy, which is the most commonly performed surgical procedure, in a general surgery clinic of a training and research hospital.

NCT ID: NCT05564286 Completed - Cervical Cancer Clinical Trials

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Start date: July 1, 2021
Phase: Phase 3
Study type: Interventional

The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly cisplatin chemotherapy in a south Chinese cohort.

NCT ID: NCT05546359 Recruiting - Clinical trials for Nausea and Vomiting, Postoperative

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Start date: January 18, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting

NCT ID: NCT05533281 Completed - Nausea and Vomiting Clinical Trials

Efficacy of Three Antiemetics in Preventing Nausea and Vomiting

Start date: September 15, 2022
Phase: Phase 4
Study type: Interventional

To explore the effect of commonly used antiemetic drugs on reducing nausea and vomiting caused by intravenous tramadol injection, so as to reduce the incidence of nausea and vomiting in clinical use of tramadol and provide guidance for the clinical use of tramadol injection

NCT ID: NCT05529004 Not yet recruiting - Clinical trials for Postoperative Nausea and Vomiting

A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy

Start date: September 2022
Phase: Phase 2
Study type: Interventional

As long as anesthesia is administered, postoperative nausea and vomiting (PONV) will continue to be a frequent and upsetting comorbidity. Vomiting and nausea can significantly slow down recovery, raise staffing and drug expenses, and decrease patient satisfaction during perioperative procedures. Nausea it is a conscious recognition of subconscious excitation in area of medulla closely associated with or a part of the vomiting center, or it is sensation of discomfort at upper abdomen and unease sensation with involuntary order to vomit. While vomiting It is a mean by which the upper GIT rides of its contents when any part of upper GIT becomes irritated, over distended or over excitable. The PONV is the most feared postoperative symptoms & it may impaired dressing , surgical repairs & increased ( bleeding , pain , risk of gastric contents aspiration ) & if it is prolonged will leads to electrolytes , fluid imbalance & dehydration ; the PONV can occurs after up to 90 % of operative procedures ; The common risk factors of PONV are : young age , female gender, history of ( PONV , motion sickness ) , those not smokers , early mobilization after surgery , early drinking & eating after operations , procedures like (laparoscopic , gynecological , abdominal , ENT , squint ) , postoperative severe pain , narcotic premedication , possibly prolonged general anesthesia , gastric distention , stimulation of the pharynx , hypoxemia , hypotension , & dehydration. The PONV can reduced by: avoidance of triggers where possible, uses of anti-emetics drugs, techniques & procedures associated with low incidence of PONV (e.g. propofol) & give intravenous fluids; with prophylaxis the incidence is usually under 30% in high risk cases, the most effective approach for prevention of PONV is the use of multiple strategies & different drugs. The pregabalin (C8H17NO2), is a newer drug & recently introduced at 1990. as anticonvulsive medication. We evaluated the effect of oral pregabalin on postoperative nausea and vomiting in laparoscopic cholecystectomy cases.

NCT ID: NCT05522023 Completed - Surgery Clinical Trials

Effects of Aromatic Solution Applied After Surgery

Start date: February 15, 2021
Phase: N/A
Study type: Interventional

Today, surgical applications are used to solve many health problems. In order for the surgical intervention to take place, anesthesia applications are often required. Complications such as sore throat, thirst and nausea and vomiting may occur as a result of trauma, local irritation and inflammation of the airway mucosa during anesthesia and tracheal intubation. These complications are in the postoperative period; It may cause delayed oral fluid intake, prolonged dehydration, oral odour, and increased risk of aspiration, hematoma and wound dehiscence due to retching and vomiting, all of which may lead to delayed discharge and increased cost. Aromatherapy, one of the non-pharmacological applications, is frequently applied in reducing postoperative complications and its effectiveness is stated. In this study, the aromatic solution applied after the surgery; It was planned to examine the effect on sore throat, thirst, nausea-vomiting. In addition, the multimodal synergistic effect of lavender oil and ginger oil used in the aromatic solution to be prepared will be utilized. As a result of this study, the effectiveness of the aromatic solution application to be applied to the patients in the postoperative period and the benefits and benefits of the patient's recovery process will be determined. Thus, effective application can be made for the entire postoperative period. It is thought that this study to be conducted will be a guide for future studies on the patient group.

NCT ID: NCT05516953 Recruiting - Morbid Obesity Clinical Trials

Baclofen in Preventing Postoperative Nausea and Vomiting After Bariatric Surgery

Start date: August 22, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to evaluate the possible efficacy of baclofen on postoperative nausea and vomiting in patient with morbid obesity who will undergo laparoscopic sleeve gastrectomy.

NCT ID: NCT05513209 Completed - Clinical trials for DECREASE POSTTONSILLECTOMY NAUSEA AND VOMITTING

Opioid Free Pterygopalatine Ganglion Block Based Multimodal Anesthesia for Tonsillectomy Operations

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

intraoperative opioid administration versus intraoperative pterygopalatine ganglion block based opioid free anesthesia to compare outcomes such as postoperative administration of opioid rates of nausea and vomiting, Post Anesthesia Care Unit (PACU) length of stay

NCT ID: NCT05509634 Completed - Clinical trials for Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Start date: September 21, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.